Am J Transplant, Volume 22, Suppl 3 Archives - Page 3 of 190 - ATC Abstracts

2022 American Transplant Congress
BiomarkeR Initiative to Advance Transplantation OutcomEs in Children (BRITE-c) Analysis
M. E. Seifert¹, L. Sheward², A. Kho², N. Rodig², V. Dharnidharka³, M. Diehl², R. B. Mannon⁴, O. Bestard⁵, T. Blydt-Hansen⁶, D. M. Briscoe²
¹University of Alabama, Birmingham, AL, ²Boston Children's Hospital, Boston, MA, ³St Louis Children's Hospital, St Louis, MO, ⁴University of Nebraska, Omaha, NE, ⁵Bellvitge University Hospital, Barcelona, Spain, ⁶BC Childrens, Vancouver, BC, Canada
*Purpose: Recent studies indicate that 25-36% of clinically stable pediatric renal transplant recipients will have subclinical rejection detected on surveillance biopsy. These findings highlight a…
2022 American Transplant Congress
Longevity Matching for Living Donor Renal Transplantation
S. Karhadkar¹, J. Dawes¹, K. Wirshup¹, J. Kolansky¹, A. Gregor¹, A. Diamond², A. DiCarlo¹
¹Temple University Hospital, Philadelphia, PA, ²-, Garnet Valley, PA
*Purpose: Living donor kidney transplantation (LDKT) continues to become a more prevalent treatment method for ESRD and is known to increase both organ availability and…
2022 American Transplant Congress
Outcomes of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Diabetic Kidney Transplant Recipients
T. S. Mahmoud¹, J. Yagan¹, A. Hasan², O. Gheith¹, M. Mostafa¹, S. Rida¹, N. El-Serwy¹, M. Shaker¹, M. Khalid¹, P. Nair¹, T. Alotaibi¹
¹Nephrology, Organ Transplant Center, Kuwait, Kuwait, ²Immunometabolism, Dasman Diabetes Center, Kuwait, Kuwait
*Purpose: The impact of the new glucose lowering therapies, sodium-glucose cotransporter 2 inhibitors (SGLT2i) and Glucagon-like peptide-1 receptor agonists (GLP-1RA), on managing patients with type…
2022 American Transplant Congress
Six-Month Outcomes Among Lung Transplant Patients with COVID-19
L. D. Mahan, J. Rose, M. Mohanka, A. Banga
UT Southwestern Medical Center, Dallas, TX
*Purpose: There is limited data on the outcomes beyond the acute illness among lung transplant (LT) patients with Coronavirus disease 2019 (COVID-19). The current study…
2022 American Transplant Congress
Risk of Post-Transplant Lymphoproliferative Disease After Anti-Thymocyte Globulin in Childhood Solid-Organ Transplant Recipients
A. M. McKay¹, C. Teoh¹, J. Vasilevska-Ristovka², J. Browne², T. Banh², A. Dipchand¹, V. Ng¹, M. Solomon¹, U. Allen¹, Y. Avitzur¹, R. Parekh³
¹Transplant & Regenerative Medicine Centre, The Hospital for Sick Children, Toronto, ON, Canada, ²Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ³Division of Nephrology, Department of Medicine, Women’s College Hospital and University Health Network, Toronto, ON, Canada
*Purpose: Determine if the use of anti-thymocyte globulin (ATG) in pediatric solid organ transplant recipients was associated with an increased risk of post-transplant lymphoproliferative disorder…
2022 American Transplant Congress
CD14⁺ Monocytes Play a Critical Role in Initiating Xeno-Recognition, Costimulation and Immune-Responses to Porcine Endothelial Cells
H. Xu, A. Kirk, H. Xu
Duke University School of Medicine, Durham, NC
*Purpose: Porcine endothelial cells (PECs) are the first barrier between a pig’s organ and circulating immune system. Unlike allogeneic immune responses, PECs fail to induce…
2022 American Transplant Congress
Do Clinical & Pathologic Signs of Rejection Develop Following Transplantation of Tissue Containing Non-Autologous Mitochondria in an Autologous Nuclear Cloned Host?
S. Jacob¹, M. L. Baack², A. Savinov³, P. J. Wettstein⁴
¹Cardiothoracic Surgery and transplantation, Mayo Clinic, Jacksonville, FL, ²Division of Neonatology, University of South Dakota – Sanford School of Medicine, Sioux Falls, SD, ³Sanford Research, University of South Dakota School of Medicine, Sioux Falls, SD, ⁴Departments of Surgery and Immunology, Mayo Clinic, Rochester, MN
*Purpose: Recent studies have yielded conflicting results on the capacity of oocyte-encoded mtDNA polymorphisms to stimulate rejection . Therefore, there are still questions as to…
2022 American Transplant Congress
BMI Trajectory and Attributable Risk of New Onset Hypertension Among Obese Living Kidney Donors
R. D. Reed¹, M. C. McLeod¹, P. A. MacLennan¹, V. Kumar¹, S. E. Brooks¹, A. G. Maynor¹, L. A. Stanford¹, G. A. Baker¹, C. A. Schinstock², J. R. Silkensen³, G. R. Roll⁴, D. L. Segev⁵, B. J. Orandi¹, C. E. Lewis⁶, J. E. Locke¹
¹Surgery, University of Alabama at Birmingham, Birmingham, AL, ²Nephrology and Hypertension, Mayo Clinic, Rochester, MN, ³Medicine, Hennepin County Medical Center, Minneapolis, MN, ⁴Surgery, University of California San Francisco, San Francisco, CA, ⁵Surgery, Johns Hopkins University, Baltimore, MD, ⁶Epidemiology, University of Alabama at Birmingham, Birmingham, AL
*Purpose: Obesity increases hypertension risk in general and living kidney donor populations. Risk attributable to donation in the context of obesity and whether that risk…
2022 American Transplant Congress
Clinical Evolution of Patients with De Novo DSA After Kidney Transplantation
C. López del Moral¹, N. Lachmann², S. Hergovits², D. Stauch², A. Akifova³, M. Naik³, B. Osmanodja³, D. Schmidt³, K. Budde³
¹Nephrology department-IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Institute for Transfusion Medicine, HLA-Laboratory, Charité - Universitätsmedizin, Berlin, Germany, ³Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin, Berlin, Germany
*Purpose: De novo donor-specific antibodies(dnDSA) are related to antibody-mediated rejection(ABMR), but the evolution of patients after dnDSA is variable and not always ABMR and graft…
2022 American Transplant Congress
Early Outcomes for Liver Transplant with Thoracoabdominal Normothermic Regional Perfusion for Donation After Circulatory Death: A Multi-Center Experience
A. L. Brubaker¹, A. Lee¹, B. Jackson¹, J. Berumen¹, J. R. Parekh¹, K. L. Mekeel¹, A. R. Gupta², J. M. Gardner², T. Chaly³, A. K. Mathur⁴, C. Jadlowiec⁴, K. Reddy⁴, R. Nunez⁴, J. Bellingham⁵, E. Thomas⁶, J. R. Wellen⁷, M. Kearns¹, V. Pretorius¹, G. T. Schnickel¹
¹UC San Diego, San Diego, CA, ²UC San Francisco, San Francisco, CA, ³Arizona Transplant Associates, Phoenix, AZ, ⁴Mayo Clinic Arizona, Phoenix, AZ, ⁵California Pacific Medical Center, Orinda, CA, ⁶University of Texas, San Antonio, TX, ⁷Washington University, Saint Louis, MO
*Purpose: We evaluated early outcomes of liver transplant after thoracoabdominal normothermic regional perfusion (TA-NRP) for controlled donation after circulatory death (cDCD) donors.*Methods: We identified liver…